C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice
Authors:
- Noritoshi NagayaNNNoritoshi Nagaya
- Takefumi ItohTITakefumi Itoh
- Takafumi FujiiTFTakafumi Fujii
- Takashi IwaseTITakashi Iwase
- Kaoru HamadaKHKaoru Hamada
- Hiroshi KimuraHKHiroshi Kimura
- Kenji KangawaKKKenji Kangawa
- 1 December 2004
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 287 (6) , L1172-L1177
Abstract
C-type natriuretic peptide (CNP) has been shown to play an important role in the regulation of vascular tone and remodeling. However, the physiological role of CNP in the lung remains unknown. Accordingly, we investigated whether CNP infusion attenuates bleomycin (BLM)-induced pulmonary fibrosis in mice. After intratracheal injection of BLM or saline, mice were randomized to receive continuous infusion of CNP or vehicle for 14 days. CNP infusion significantly reduced the total number of cells and the numbers of macrophages, neutrophils, and lymphocytes in bronchoalveolar lavage fluid. Interestingly, CNP markedly reduced bronchoalveolar lavage fluid IL-1β levels. Immunohistochemical analysis demonstrated that CNP significantly inhibited infiltration of macrophages into the alveolar and interstitial regions. CNP infusion significantly attenuated BLM-induced pulmonary fibrosis, as indicated by significant decreases in Ashcroft score and lung hydroxyproline content. CNP markedly decreased the number of Ki-67-positive cells in fibrotic lesions of the lung, suggesting antiproliferative effects of CNP on pulmonary fibrosis. Kaplan-Meier survival curves demonstrated that BLM mice treated with CNP had a significantly higher survival rate than those given vehicle. These results suggest that continuous infusion of CNP attenuates BLM-induced pulmonary fibrosis and improves survival in BLM mice, at least in part by inhibition of pulmonary inflammation and cell proliferation.Keywords
This publication has 23 references indexed in Scilit:
- Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2001
- Increased Expression of Platelet-Derived Growth Factor A and Insulin-Like Growth Factor-I in BAL Cells During the Development of Bleomycin-Induced Pulmonary Fibrosis in MiceChest, 1996
- Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silicaCytokine, 1993
- Vascular natriuretic peptideThe Lancet, 1992
- Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system".Journal of Clinical Investigation, 1992
- Mechanisms of bleomycin-induced lung damageArchives of Toxicology, 1991
- C-Type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brainBiochemical and Biophysical Research Communications, 1990
- Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.Journal of Experimental Medicine, 1989
- Simple method of estimating severity of pulmonary fibrosis on a numerical scale.Journal of Clinical Pathology, 1988
- Rapid, simultaneous and sensitive determination of free hydroxyproline and proline in human serum by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1982